Charlie is currently the CSO of Affinia Therapeutics, a company devoted to developing the next generation of gene therapy by improved targeting of AAV. Prior to Affinia, Charlie was chief scientific officer at Editas Medicine where his research group advanced the pioneering CRISPR gene-editing platform and medicines from program inception to Investigational New Drug (IND) application. He has led research activities at both biotech and big pharma companies across a range of therapeutic areas, including neurology, neuromuscular, cardiovascular, ophthalmology, and oncology. Prior to Editas, he was vice president of genetically-defined diseases and genomics at Bristol Myers Squibb Company, where he was responsible for developing the group’s strategy and building a pipeline of novel therapeutics with a focus on central nervous system (CNS) and cardiovascular rare diseases. Before joining the industry, Charlie held academic positions at Vanderbilt University and Whitehead Institute for Biomedical Research. Charlie received a Bachelor of Science in chemical engineering and a doctorate in biology from Massachusetts Institute of Technology.